Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia affecting over 5.5 million people worldwide. The most serious consequence of AF is ischaemic stroke. It is estimated that up to 20% of all strokes are related to AF. the most common and effective treatment is the use of the blood thinning medication Warfarin. Despite its proven efficacy, Warfarin therapy is not well-tolerated or may be difficult to control in many patients. The WATCHMAN LAA Closure Technology is a device alternative to Warfarin therapy in patients with non-valvular atrial fibrillation. By closing off the Left Atrial Appendage, the WATCHMAN Technology is designed to reduce the risk of stroke, cardiovascular death and systemic embolisation, potentially eliminating the need for long term Warfarin therapy.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia affecting over 5.5 million people worldwide. The most serious consequence of AF is ischaemic stroke. It is estimated that up to 20% of all strokes are related to AF. the most common and effective treatment is the use of the blood thinning medication Warfarin. Despite its proven efficacy, Warfarin therapy is not well-tolerated or may be difficult to control in many patients. The WATCHMAN LAA Closure Technology is a device alternative to Warfarin therapy in patients with non-valvular atrial fibrillation. By closing off the Left Atrial Appendage, the WATCHMAN Technology is designed to reduce the risk of stroke, cardiovascular death and systemic embolisation, potentially eliminating the need for long term Warfarin therapy.
presentations
Introduction - Part 1 - Ken Stein, Boston Scientific
Introduction - Part 2 - Ken Stein, Boston Scientific
The Watchman LAA: latest clinical study results - Part 1
The Watchman LAA: latest clinical study results - Part 2
Interdisciplinary approach in stroke prevention - Part 1
Interdisciplinary approach in stroke prevention - Part 2
Joining forces in the fight against stroke - Part 1 - Trudie Lobban, CEO AFA (UK)
Joining forces in the fight against stroke - Part 2 - Trudie Lobban, CEO AFA (UK)
Question and Answers - Part 1
